<DOC>
	<DOC>NCT02211989</DOC>
	<brief_summary>To investigate safety, tolerability and pharmacokinetics, and pharmacodynamics of BI 14332 CL</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy males were included based on a complete medical history, including the physical examination, vital signs (BP, HR), 12lead ECG, and clinical laboratory tests Age ≥18 and Age ≤50 years Body Mass Index (BMI) ≥18.5 and BMI ≤29.9 kg/m2 Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation Any finding of the medical examination (including BP, HR and ECG) deviating from normal and of clinical relevance Any evidence of a clinically relevant concomitant disease Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders History of relevant orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) Intake of drugs with a long halflife (&gt;24 hours) within at least one month or less than 10 halflives of the respective drug prior to administration or during the trial Use of drugs which reasonably influenced the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial Participation in another trial with an investigational drug within two months prior to administration or during the trial Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day) Inability to refrain from smoking on trial days Alcohol abuse (more than 60 g/day) Drug abuse Blood donation (more than 100 mL within four weeks prior to administration or during the trial) Excessive physical activities (within one week prior to administration or during the trial) Any laboratory value outside the reference range and of clinical relevance Inability to comply with the dietary regimen of the study centre Any ECG value outside the reference range and of clinical relevance including, but not limited to QRS interval &gt;120 ms or a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval &gt;450 ms or QT &gt;500 ms) A history of additional risk factors for Torsades des Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) The use of concomitant medications that prolong the QT/QTc interval</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>